Brazil HIV Therapeutics Market Analysis Report [2022-30] I Insights10

Brazil HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Brazil HIV therapeutics market will reach a value of $460.03 Mn from $344 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030. The market is primarily dominated by local players such as EMS, Eurofarma Laboratórios, and Ache Laboratorios Farmacéuticos. The market for HIV/AIDS treatment in Brazil is primarily driven by government funding and initiatives, social issues like stigma and discrimination, and diagnostic tools. The HIV therapeutics market in Brazil is segmented by type, product, geography, end user, and distribution channel.

ID: IN10BRPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Brazil AUTHOR: Dr. Vishwa Modhia

Buy Now

Brazil HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Brazil HIV therapeutics market will reach a value of $460.03 Mn from $344 Mn in 2022, growing at a CAGR of 3.7% during 2022-2030.

In Brazil, the adult HIV/AIDS prevalence rate is anticipated to be 0.6% by 2021. There are about 960,000 HIV-positive people in Brazil. In terms of other countries, Brazil is ranked 53rd for HIV prevalence. In 2019, the Brazilian government’s healthcare expenditures accounted for 9.6% of its GDP.

In Brazil, ART (anti-retroviral treatment) is administered to about 73% of HIV-positive individuals. The HIV-related expenditure in Brazil is $501 Mn. With an estimated 730,000 people living with HIV in the nation, Brazil has one of the worst HIV/AIDS epidemics in the world. Given that the disease continues to affect a sizable portion of the population, the government and healthcare providers are very concerned about the HIV/AIDS market in Brazil.

brazil HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

The Brazilian government has put in place a number of programs to address the HIV/AIDS problem, including expanding access to testing and care, increasing public knowledge of the condition, and lessening stigma. In order to create new drugs and diagnostic equipment to treat HIV/AIDS, the government has also made research investments.

Market Restraints

The use of ART has led to a significant decline in HIV/AIDS-related deaths in Brazil, but there have been reports of resistance to some of the drugs used in ART, which can make it more difficult to effectively treat the disease.

The Brazilian government has invested significant resources in the fight against HIV/AIDS, however, the country's economy has faced some challenges and the government has had to cut down on some of its expenses, this could affect the funds available for the fight against HIV/AIDS.

Competitive Landscape

Key Players

Ache Laboratorios Farmacéuticos (BRA)
Eurofarma Laboratórios (BRA)
EMS (BRA)
Cristália (BRA)
Prati-Donaduzzi (BRA)
Pfizer
Bristol-Myers Squibb
GlaxoSmithKline

Recent Notable Updates

March 2022: In South Africa and Brazil, the first injection that provides long-term HIV protection is being introduced as an alternative to daily medication. In Brazil, 30% of transgender people living with HIV, and 18% of men who have sex with men are receiving long-acting cabotegravir injections.

Healthcare Policies

Local health authorities in states and municipalities as well as the National Health Surveillance Agency ("ANVISA"), a federal organization connected to the Ministry of Health, serve as authorities in Brazil. Depending on the link in the marketing chain, the Drug Market Regulation Chamber (CMED) determines the maximum price that can be charged for a drug. The Chamber also chooses the price reduction the government body should use to buy drugs.

Reimbursement Scenarios

Brazil's Unified Health System (SUS) is funded by fines, fees, donations, the federal government's social welfare budget, the states, the Federal District, and the municipalities, and provides free and universal coverage. The SUS offers financial support to private healthcare institutions through financial grants and reimbursement for medical procedures, devices, and drugs following the signing of an agreement between the private entity and the Ministry of Health.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.